Tag Archive for: Parkinson’s disease

Lario Therapeutics awarded $2.4m by The Michael J. Fox Foundation and Wellcome to expand neuronal calcium channel platform across CNS disorders

/in

New prestigious grants support Lario’s unique portfolio of calcium channel programmes Indication expansion into Parkinson’s disease, and PTSD (post-traumatic stress disorders) Builds on prior support from The Michael J. Fox Foundation and further validates Lario’s precision neuroscience platform Edinburgh, UK – 19 February 2026 – Lario Therapeutics (“Lario” or the “Company”), a biopharmaceutical company developing […]

Read more

Neuraxpharm and Dizlin Pharmaceuticals Announce Global Strategic Co-Development Agreement Bringing Next-Generation Drug-Device Therapy to Patients with Advanced Parkinson’s Disease

/in

Infudopa SubC® is a user-friendly and minimally invasive alternative enabling flexible dosing and thereby empowering patients with greater independence Düsseldorf, Germany and Gothenburg, Sweden – 8 July 2025 – Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company dedicated to central nervous system (CNS) disorders, and Dizlin Pharmaceuticals AB (“Dizlin”), a Swedish R&D company focused […]

Read more

Alchemab advances a novel antibody with potential in Parkinson’s disease with support from The Michael J. Fox Foundation

/in

Cambridge, UK, 06 June 2024 – Alchemab Therapeutics (Alchemab), an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announces that it has been awarded a grant of US$595,000 by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support its Parkinson’s disease program. The grant will fund research performed at […]

Read more